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What you need to know
• Liver ultrasonography is a pragmatic first line test to diagnose hepatic
steatosis and exclude other liver pathology in those with non-alcoholic
fatty liver disease (NAFLD)
• In patients with confirmed hepatic steatosis, use simple non-invasive
markers of fibrosis (such as an enhanced liver fibrosis blood test (ELF))
and/or FibroScan to investigate for liver fibrosis
• Offer patients with hepatic fibrosis referral for specialist opinion, as
hepatic fibrosis is the strongest predictor of overall and liver related
mortality in those with NAFLD
At a routine work health check, a 52 year old sedentary
computer programmer was found to have a serum alanine
aminotransferase (ALT) concentration of 68 IU/L (normal 0-40
IU/L), and a triglyceride concentration of 1.9 mmol/L. His
fasting plasma glucose level was 5.8 mmol/L and other basic
liver, renal, and lipid blood tests were normal. He had an
unremarkable medical history and took no regular medications,
did not smoke, and consumed <7 units of alcohol/week. Clinical
examination was unremarkable. His body mass index was 29
kg/m2; waist circumference 102 cm, and blood pressure 134/88
mmHg. A repeat serum ALT measurement remained raised some
months later, at 62 IU/L.
Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver
disease that encompasses a spectrum of progressive pathological
conditions, ranging from non-alcoholic fatty liver (NAFL) to
steatohepatitis (NASH), fibrosis, and cirrhosis. When hepatic
steatosis occurs in the absence of excessive alcohol consumption
and other recognised causes of liver fat, and with
cardiometabolic risk factors, it is likely that the diagnosis is
NAFLD as NAFLD is principally a diagnosis of exclusion.
NAFLD is the commonest liver disease in high income
countries, and is estimated to affect at least 25%-30% of adults
in the general population and up to 70%-90% of persons with
obesity or type 2 diabetes.1NAFLD is associated not only with
liver related morbidity and mortality, but also with an increased
risk of developing cardiovascular disease and type 2 diabetes.2 3
Liver biopsy remains the reference method for diagnosing
NAFLD, as it provides the most accurate assessment of disease
grade and stage.4 5 However, undertaking a liver biopsy is costly,
risky, and potentially painful. Moreover, interpretation of
NAFLD severity can be compromised by sampling errors in
what can be a patchy disease.6 7
In this article, we discuss the diagnosis of NAFLD, testing for
liver fibrosis in those with NAFLD, and monitoring of those
most likely to develop advanced liver disease. We examine the
evidence and guidelines from Europe, the United States, and
the UK’s National Institute for Health and Care Excellence
(NICE)8-10 for and against the use of specific diagnostic tests.
Our approach to the use of liver ultrasound in establishing a
diagnosis of hepatic steatosis differs from the recent NICE
guidelines,10 but complements British Society of
Gastroenterology guidelines.11 Treatment options are beyond
the scope of this article.
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What are the next investigations?
After performing a history and examination, the next
investigations to establish whether the patient has NAFLD or
another liver condition are:
•A non-invasive liver screen, which includes tests such as
serology for hepatitis B and C viruses, and measurement
of liver auto-antibodies, immunoglobulins, caeruloplasmin,
alpha 1 anti-trypsin, and ferritin concentrations
•A liver ultrasound to look for features suggestive of
NAFLD (hepatic steatosis) and to rule in or out other
pathology.
An ultrasound scan of the liver is the most typical imaging test
requested by non-specialists in patients in whom NAFLD is
suspected. This is because it can help to confirm and exclude
other causes of liver disease such as gall stones or metastasis,
as well as confirm hepatic steatosis. Although the NICE
guidelines state that ultrasonography is “not cost effective,”3 it
is important to understand why such a statement was made,
despite widespread acceptance that the most useful imaging
technique to detect steatosis is ultrasonography.1 2 12 In estimating
the cost effectiveness of any test or intervention, what is
considered is not only the cost, but also the relationship between
the measured factor (ie, hepatic steatosis) and the outcome.
Ultrasonography enables an accurate diagnosis of hepatic
steatosis, but the presence of steatosis does not predict risk of
end-stage liver disease. Rather, it is advanced fibrosis (which
is not accurately detected by ultrasonography) that more
accurately predicts the risk of developing end-stage liver disease
and hepatocellular carcinoma.13-16 Ultrasonography is, however,
a pragmatic approach to investigating the possibility of NAFLD
because it also allows the exclusion of other liver conditions
and so is central to the approach laid out in this article.
A validated, widely accepted procedure for the diagnosis and
monitoring of NAFLD does not yet exist. We propose a potential
approach (infographic) including “red flags” and when to seek
specialist advice. The infographic gives an overview of testing
for NAFLD and excluding other pathologies in a person with
abnormal liver function test results. The graphic includes
features of abnormal liver function tests and factors that are
useful to note in the history and examination. It provides
information about further testing in those identified with NAFLD
to diagnose liver fibrosis, and about how to monitor those found
to have advanced fibrosis.
Is it NAFLD or something else?
When hepatic steatosis occurs in the absence of recognised
causes of liver fat (table 1), and with cardiometabolic risk factors
(table 2), it is likely that the diagnosis is NAFLD.
NAFLD might be suspected because the patient is overweight
or obese, has type 2 diabetes, or has other metabolic syndrome
features.17 More often, a diagnosis of NAFLD is suspected when
liver blood tests show mild to moderate elevations of serum
aminotransferase levels. However, serum aminotransferase
levels are not sensitive or specific to make or rule out a diagnosis
of NAFLD. Table 2 describes these risk factors. Be aware that
NAFLD can also occur in non-obese or lean individuals (termed
“lean NAFLD”).
An alternative pathology might be more likely if a non-invasive
liver screen of other factors in the history, such as high alcohol
intake, suggests another cause (table 1).
What techniques can be used to test for
hepatic steatosis?
The presence of hepatic steatosis, and therefore NAFLD, can
be diagnosed by various methods (table 3).
Ultrasonography is the first line imaging technique for
diagnosing hepatic steatosis. Compared with histology, it has
a good sensitivity (~85%) and specificity (~95%) for detecting
moderate steatosis,15 16 and traditionally its sensitivity is thought
to be poor when <20%-30% of hepatocytes are steatotic.22
Combining standard ultrasonography with computer software
technology (MATLAB) (eg, combined ultrasound hepatic/renal
ratio and hepatic echo-intensity attenuation rate evaluation)18
improves the sensitivity of ultrasonography further. In this
methodology, the ultrasound hepatic/renal echo-intensity ratio
and ultrasound hepatic echo-intensity attenuation rate were
obtained from ordinary ultrasound images using the MATLAB
program. Compared with proton magnetic resonance
spectroscopy (ie, the gold standard for detecting low levels of
liver fat content) (see table 3), at levels of <15% liver fat content,
the sensitivity and specificity of the ultrasound quantitative
model was 81.4% and 100%.
Computed tomography, magnetic resonance imaging, and
magnetic resonance spectroscopy can be used, but such imaging
techniques are more expensive and less readily available.8 9
Some non-invasive biomarkers of steatosis (eg, fatty liver index)
have been proposed, but they have limited clinical utility, as
they often do not accurately quantify steatosis as assessed
histologically. Controlled attenuation parameter (CAP, assessed
by transient elastography) can also be used, although it remains
uncertain what CAP thresholds should be adopted to diagnose
steatosis.23
Liver biopsy remains the reference method for diagnosing and
staging NAFLD, but is not a practical first line investigation.
Undertaking serial liver biopsies over time is fraught with
difficulties, and is unacceptable to monitor disease. Nevertheless,
biopsy is the only method for diagnosing inflammation in
NAFLD (ie, NASH), and should also be also considered when
other chronic liver diseases cannot be definitively excluded.
For those with NAFLD, what further
investigations are offered?
Previously thought to be a harmless condition, hepatic steatosis
is now increasingly being recognised as a cause of progressive
and advanced liver disease. Recent follow-up studies showed
that, contrary to conventional paradigm, patients with NAFL
(ie, simple steatosis on histology) can develop progressive liver
fibrosis.24 Hepatic steatosis (detected by ultrasonography) is
also strongly associated with an increased risk of fatal and
non-fatal cardiovascular disease, type 2 diabetes, and chronic
kidney disease.2 3 After a diagnosis of hepatic steatosis has been
established, strong evidence8-10 now indicates that it is clinically
more important to stage liver fibrosis than to ascertain the
presence of NASH.
Characterise the severity of NAFLD
Once steatosis has been diagnosed, the presence and severity
of liver fibrosis should be assessed using combined non-invasive
tests to identify those individuals with advanced fibrosis who
should be referred to specialists in hepatology for further
investigations. Staging of liver fibrosis can be undertaken with
the use of biopsy or various non-invasive tests9 25 (table 4).
Choice of test will depend on local availability. The infographic
outlines two possible approaches. Tests such as Fibrosis-4 score
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(FIB4), NAFLD fibrosis score (NFS), and enhanced liver
fibrosis (ELF) can be conducted by non-specialists. How they
are calculated is outlined at the foot of table 4.
The ELF test (a commercial blood test using three direct fibrosis
biomarkers) has good performance for diagnosing significant
and advanced fibrosis, and it is now strongly recommended by
the NICE guidelines, although it is not used worldwide. Other
“biochemical” score systems (eg, the NFS and FIB4 scores,
which are both cost effective and highly sensitive tools to
exclude patients with advanced fibrosis) and second line
“physical” techniques (liver stiffness measurements assessed
with transient elastography [FibroScan] or with newer imaging
techniques) are frequently used to assess the severity of liver
fibrosis. The combination of FibroScan with FIB4/NFS
measurements has shown excellent accuracy in distinguishing
advanced fibrosis.25
All non-invasive tests for liver fibrosis are better at excluding
advanced fibrosis than diagnosing it. They have only modest
positive predictive value for advanced fibrosis, but a much
stronger negative predictive value. Furthermore, none is good
at detecting intermediate stages of fibrosis. As such, no test can
fully replace liver biopsy. For example, the NAFLD fibrosis
score, the most widely validated non-invasive test, has good
performance for identifying patients without fibrosis, but poorer
performance for diagnosing clinically significant and advanced
fibrosis. As recommended by the European8 and American9
practice guidelines, current non-invasive tests of fibrosis should
be used in a staged approach, utilising their high negative
predictive value to rule out patients who are unlikely to have
advanced fibrosis, and so reserving liver biopsy for patients
who are most likely to have substantial (clinically significant)
fibrosis or when there is diagnostic uncertainty.
Outcome
The man’s general practitioner requested a liver ultrasound scan
(confirming the presence of hepatic steatosis) together with a
repeat serum ALT measurement of 62 IU/L. Other blood tests
(including serology for hepatitis B and C viruses, liver
auto-antibodies, immunoglobulins, caeruloplasmin, alpha-1
antitrypsin and ferritin levels) excluded other causes of liver
disease.
The patient is likely to have NAFLD.
How this article was made
We searched PubMed for original articles and reviews using the keywords
“nonalcoholic fatty liver disease,” or “fatty liver” combined with “diagnosis,”
“prognosis,” or “mortality” published between 1990 and 2018. Articles published
in languages other than English were excluded from the analysis.
How patients were involved in the creation of this article
Several of our patients have told us that doctors are inconsistent in their
approaches to investigating their liver disease. Two patient representatives
(Irene McGill, who has NAFLD, and Jane Putsey, who has cared for her father
with NAFLD) participated in the NICE NAFLD NG 49 Guideline Development
Group and contributed to the guideline. Ms McGill and Ms Putsey advised
Professor Byrne of what they thought was important for patients with NAFLD,
which influenced the writing of this manuscript. Both representatives
commented on the article and gave helpful suggestions to drafts of the
manuscript to improve its clarity. For example, they asked for clear information
on how NAFLD could be diagnosed.
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Tables
Table 1| Tests and factors which do not suggest NAFLD
Factors that do not suggest NAFLDRisk factors for liver disease
History of excessive alcohol consumptionAlcohol
>21 standard drinks per week in men and >14 standard drinks per week
in women *
History of drug exposureDrugs
Valproic acid, oestrogens, tamoxifen, corticosteroids, tetracycline,
amiodarone, perhexiline maleate, methotrexate,
4,4′-diethylaminoethoxyhexesterol, chloroquine, L-asparaginase
Serological positivity for HBsAg and anti-hepatitis C antibodies/HCV-RNAViral hepatitis
High transferrin saturation (>45%); high serum ferritin (>1000 μg/L)Haemochromatosis
Serum: Immunoglobulins (IgG) raised; anti-mitochondrial antibodies+ve; smooth muscle
cell antibodies strongly+ve; anti-nuclear antibodies+ve; anti-liver kidney microsomal+ve
Autoimmune hepatitis **
Low level of caeruloplasmin (<200 mg/L)Wilson’s disease ***
Low level of α 1 anti-trypsin protein (<260 micromol/L)Alpha 1 anti-trypsin deficiency
Anti-tissue transglutaminase antibodies+veCoeliac disease
Occupational exposure to hepatoxins; malnutrition (especially Kwashiorkor); total parenteral
nutrition; rapid weight loss; surgically altered bowel anatomy (eg, jejuno-ileal bypass,
extensive small-bowel resection); lipodystrophy; hypobetalipoproteinaemia
Others
* The alcohol thresholds for liver disease reported in table 1 are not entirely congruent with the UK current thresholds for safe alcohol consumption, which are >14 units
(standard drinks) per week in both men and women. ** Low titres of anti-nuclear, anti-smooth muscle, and anti-mitochondrial antibodies can be noted in patients with
NAFLD (in the absence of autoimmune hepatitis) ***Slightly lower caeruloplasmin levels can also be found
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Table 2| Common cardiometabolic risk factors for NAFLD
Diagnostic criteria of the risk factorMetabolic abnormalitiesRisk factor
Apply ethnic specific cut-offs for body mass index, eg, white European
≥25/ ≥30 kg/m2
Overweight/obesity
Apply ethnic specific cut-offs for waist circumference, eg, white European
>94/80 cm (M/F)
Abdominal obesityMetabolic syndrome features
≥1.7 mmol/L or lipid lowering treatmentHigh serum triglycerides
≥130/85 mmHg or anti-hypertensive treatmentIncreased blood pressure/hypertension
<1.0/1.3 mmol/L (M/F)Low HDL cholesterol
Fasting glucose levels ≥5.6 mmol/LImpaired fasting glycaemia
Fasting glucose levels ≥7 mmol/L or glucose lowering treatmentType 2 diabetes mellitus
Other modifiable risk factors for NAFLD are cigarette smoking (due to its pro-fibrotic hepatic effect), excessive dietary intakes of fructose, carbohydrates, and
saturated fatty acids
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Table 3| Invasive and non-invasive techniques for diagnosing hepatic steatosis in NAFLD
Pros and cons of techniqueResult compatible with NAFLDTechnique
Reference method for diagnosing NAFLD and where there is
diagnostic uncertainty. Expensive, invasive, substantial morbidity
and even mortality (rarely). Not suitable for detailed monitoring
of disease
Histological examination shows lipid droplets in at least
5% of hepatocytes
Biopsy
The sensitivity of ultrasound is poor below levels of fat infiltration
<20%-25%; however, the technique is highly sensitive and
specific at higher levels of fat infiltration. Combining standard
ultrasound with computer software technology (MATLAB) (eg,
combined ultrasound hepatic/renal ratio and hepatic
echo-intensity attenuation rate evaluation,18 improves the
sensitivity of ultrasound even further
Liver echogenicity exceeds that of renal cortex and
spleen and there is attenuation of the ultrasound wave,
loss of definition of the diaphragm, and poor delineation
of the intrahepatic architecture
Ultrasonography
Inexpensive, but requires waist circumference measurements.
Not validated against liver histology
FLI ≥60 suggestive of hepatic steatosis and validated
against ultrasound,19 or magnetic resonance
spectroscopy (MRS)20
Fatty liver index (FLI) (algorithm derived
score using body mass index, waist
circumference, fasting serum triglycerides,
and gamma-glutamyltransferase
concentrations)
Inexpensive, but requires serum insulin and AST measurements.
Not validated against liver histology
Optimal cut-off point=-0.640 for diagnosing hepatic
steatosis on MRS21
NAFLD liver fat score (algorithm derived
score using the presence of metabolic
syndrome and type 2 diabetes, fasting
serum insulin, AST, and the AST/alanine
aminotransferase ratio)
Transient elastography is a promising technique, but further
evidence and validation of its utility for diagnosing hepatic
steatosis (by CAP measurement) is required. The signal can be
affected in severely obese patients
Optimal controlled attenuation parameter (CAP)
thresholds ≥248, ≥268 dB/m for those above stage 1
steatosis grade, respectively12
Transient elastography (FibroScan)
Good for investigating other potential abdominal pathologies.
Computed tomography has limited sensitivity to detect low levels
(<30% liver fat) and exposes the patient to substantial levels of
radiation
Attenuation of the liver is at least 10 Hounsfield units
(HU) less than that of the spleen, or attenuation of the
liver less than 40 HU13
Computed tomography
MRI and MRS are very sensitive non-invasive techniques for
diagnosing liver fat, but are currently expensive techniques for
this indication
MRI: Chemical shift gradient echo imaging with
in-phase and opposed-phase acquisitions identifying
≥5.5% liver fat accumulation. MRS: Proton MRS
identifying ≥5.5% liver fat accumulation14
Magnetic resonance imaging (MRI) or
magnetic resonance spectroscopy
(MRS)
Combining standard ultrasonography with computer software technology (MATLAB) (eg, combined ultrasound hepatic/renal ratio and hepatic echo-intensity
attenuation rate evaluation)18 improves the sensitivity of ultrasonography. Compared with proton-magnetic resonance spectroscopy (ie, the gold standard for
detecting low levels of liver fat content), at levels of <15% liver fat content, the sensitivity and specificity of the ultrasound quantitative model was 81.4% and 100%.
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Table 4| Invasive and non-invasive techniques for diagnosing advanced fibrosis in NAFLD
Result compatible with NAFLDTechnique
Advanced fibrosis thresholds=F3 or F4 stages
Fibrosis may vary from no fibrosis (F0), portal fibrosis without septa (F1), portal fibrosis




Fibrosis-4 score (FIB4) >2.6726
NAFLD fibrosis score (NFS) >0.67627




Vibration controlled transient elastography >8.7 kPA29 30




Acoustic radiation force impulse elastography (ARFI)
Advanced fibrosis threshold
MRE >3.6432
Magnetic resonance imaging techniques eg, magnetic resonance
elastography (MRE)
1 The FIB4 score is calculated as (age×AST)÷(platelet count×√ALT) 2. The NFS is calculated as follows:−1.675+0.037×age+0.094×BMI+1.13×IFG or diabetes (yes=1,
no=0)+0.99×AST/ALT ratio−0.013×platelet count−0.66×serum albumin 3. The ELF score is a commercial blood test that combines quantitative measurements of three
serum direct fibrosis biomarkers (ie, tissue inhibitor of metalloproteinase 1, procollagen III N-terminal peptide, and hyaluronic acid) to a single value. In a recent
meta-analysis, the summary sensitivities and specificities of ELF score for detecting significant fibrosis were 83% and 73%, respectively; those for detecting advanced
fibrosis were 78% and 76%, whereas those for detecting cirrhosis were 80% and 71%, respectively.33 4. In a recent meta-analysis, the summary sensitivities and
specificities of FibroScan with the M probe (threshold of 8.7-9.0 kPA) for detecting advanced fibrosis were 87% and 79%, respectively.30 A Fibroscan with the XL probe
has also been validated for severely obese patients, and has a diagnostic accuracy substantially comparable with that of the standard M probe 5. Magnetic resonance
elastography has the highest diagnostic accuracy for staging fibrosis in NAFLD. Patients with NASH might or might not have substantial liver fibrosis. The “gold standard”
for diagnosis of NASH is only liver biopsy, with evidence of hepatocellular ballooning and Mallory bodies.
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